Advertisement
Organisation › Details
Ascendis Pharma A/S (Nasdaq: ASND)
Ascendis Pharma is an emerging pharmaceutical
company which is creating improved, patentable versions of both currently marketed
drugs and high-value development-stage opportunities. The company is built upon a
novel transient linker technology, which conjugates peptides, proteins and small
molecules to a carrier molecule in a reversible fashion. This unique reversibility
allows an unmodified active drug to be released (unlinked) in the body in a precise,
time-controlled fashion, creating a long-acting effect. Conventional conjugation
technologies are unable to achieve this type of slow-release mechanism because the
polymer cannot de-link from the drug.
Ascendis’ commercial headquarters is based in Copenhagen, Denmark. Its research
organization, formerly known as Complex Biosystems, is located in Heidelberg,
Germany. The expertise at the two sites creates a continuum from discovery to
clinical development and commercialization that facilitates rapid product
development. *
Start | 2007-12-01 established | |
Group | Ascendis Pharma (Group) | |
Today | Ascendis Pharma (Group) | |
Industry | TransCon technology | |
Industry 2 | pharmaceutical | |
Person | Mikkelsen, Jan (Ascendis Pharma 201609 CEO) | |
Person 2 | Smith, Scott T. (Ascendis Pharma 201609 CFO) | |
Region | Hellerup | |
Country | Denmark | |
Street | 12 Tuborg Boulevard | |
City | 2900 Hellerup | |
Tel | +45-3694-4486 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | D: 101 to 500 (2017-12-31) |
Currency | EUR | |
Annual sales | 1,530,000 (revenue, consolidated (2017) 2017-12-31) | |
Profit | -123,897,000 (2017-12-31) | |
Cash | 690,400,000 (2019-06-30) | |
* Document for »About Section«: | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Ascendis Pharma (Group)
- [1] Ascendis Pharma A/S. (8/31/21). "Press Release: Ascendis Pharma A/S Announces Proposed Public Offering of ADSs". Copenhagen....
- [2] Ascendis Pharma A/S. (5/11/20). "Press Release: Ascendis Pharma A/S Will Appoint Jesper Høiland as Global Chief Commercial Officer". Copenhagen....
- [3] Ascendis Pharma A/S. (8/29/19). "Press Release: Ascendis Pharma A/S Announces Three Investor Presentations in September". Copenhagen....
- [4] Ascendis Pharma A/S. (8/28/19). "Press Release: Ascendis Pharma A/S Reports Second Quarter 2019 Financial Results". Copenhagen....
- [5] Ascendis Pharma A/S. (3/4/18). "Press Release: Ascendis Pharma Announces Once-weekly TransCon Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency"....
- [6] Ascendis Pharma A/S. (3/4/18). "Press Release: Ascendis Pharma A/S Announces Proposed Public Offering of ADSs". Copenhagen....
- [7] Ascendis Pharma A/S. (4/2/18). "Press Release: Ascendis Pharma A/S Appoints Thomas A. Larson as Chief Commercial Officer". Copenhagen....
- [8] Ascendis Pharma A/S. (3/28/18). "Press Release: Ascendis Pharma A/S Reports Full Year 2017 Financial Results". Copenhagen....
- [9] Ascendis Pharma A/S. (2/21/18). "Press Release: Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs". Copenhagen....
- [10] Ascendis Pharma A/S. (2/20/18). "Press Release: Ascendis Pharma A/S Announces Proposed Public Offering of ADSs". Copenhagen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top